Study of Circulating Tumour DNA to Improve Diagnosis and Monitoring of Oropharyngeal Squamous Cell Carcinoma Including HPV-positive and HPV-negative Types

What this Trial Is About

Oropharyngeal squamous cell carcinoma OPSCC is a common type of throat cancer in Scotland that has been increasing, especially cases linked to human papillomavirus HPV. This research evaluates blood-based tests that detect tumour DNA fragments in the blood, aiming to improve diagnosis, monitor treatment response, identify early relapse, and assist clinical decisions for both HPV positive and negative OPSCC patients. The study focuses on developing advanced genetic assays to improve patient care and quality of life. The study involves analyzing circulating tumour-derived DNA ctDNA from blood samples, known as liquid biopsy, which is less invasive than surgical biopsy. Researchers will expand their current group of HPV positive patients to assess the clinical value of HPV DNA analysis in blood for monitoring treatment and relapse. For HPV negative patients, new diagnostic tests will be developed using genomic analysis of tumour and blood DNA to find biomarkers and targets for personalized treatment. Participants will provide blood samples that will be regularly tested to track tumour DNA levels, helping to assess treatment success and detect relapse early. Researchers will measure tumour burden over a three-year period using sensitive DNA detection methods. The study will monitor both HPV positive and negative patients with OPSCC to improve disease management. Participation involves ongoing follow-up to understand how tumour DNA in blood reflects treatment outcomes and disease progression.

The Role of Circulating Tumour DNA in Head and Neck Cancer